Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause Type 2 diabetes mellitus? 2,909 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 2,909 reports of Type 2 diabetes mellitus have been filed in association with INFLIXIMAB (Renflexis). This represents 2.1% of all adverse event reports for INFLIXIMAB.

2,909
Reports of Type 2 diabetes mellitus with INFLIXIMAB
2.1%
of all INFLIXIMAB reports
1,754
Deaths
1,796
Hospitalizations

How Dangerous Is Type 2 diabetes mellitus From INFLIXIMAB?

Of the 2,909 reports, 1,754 (60.3%) resulted in death, 1,796 (61.7%) required hospitalization, and 1,865 (64.1%) were considered life-threatening.

Is Type 2 diabetes mellitus Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 2,909 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Condition aggravated (16,616) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173)

What Other Drugs Cause Type 2 diabetes mellitus?

ATORVASTATIN (7,556) ADALIMUMAB (3,516) PREDNISONE (3,484) METHOTREXATE (3,465) RITUXIMAB (3,318) TOCILIZUMAB (3,145) ABATACEPT (3,074) LEFLUNOMIDE (3,033) ALENDRONATE (3,002) DICLOFENAC (2,974)

Which INFLIXIMAB Alternatives Have Lower Type 2 diabetes mellitus Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All Type 2 diabetes mellitus Reports All Drugs Causing Type 2 diabetes mellitus INFLIXIMAB Demographics